Please wait while the formulary information is being retrieved.
LUMOXITI (moxetumomab pasudotox-tdfk)
- Hairy cell leukemia
1 mg intravenous solution
- Infuse 0.04 mg/kg over 30 minute(s) by intravenous route on days 1, 3, and 5 of a 28-day cycle
Hairy cell leukemia
- Infuse 0.04 mg/kg over 30 minute(s) by intravenous route on days 1, 3, and 5 of a 28-day cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Hemolytic uremic syndrome
Contraindicated
- Kidney disease with reduction in GFR
- Pregnancy
Severe
Moderate
- Hypocalcemia
LUMOXITI (moxetumomab pasudotox-tdfk)
- Hairy cell leukemia
- Anemia
- Capillary leak syndrome
- Hypoalbuminemia
- Hypocalcemia
- Hypophosphatemia
- Kidney disease with reduction in GFR
- Nephrotoxicity
- Neutropenic disorder
- Body fluid retention
- Chills
- Constipation
- Diarrhea
- Edema
- Fatigue
- Fever
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Ascites
- Conjunctival hemorrhage
- Hemolytic uremic syndrome
- Hypertension
- Hypotension
- Pericardial effusion
- Pleural effusions
- Renal failure
- Thrombocytopenic disorder
- Abdominal distension
- Blurred vision
- Cataracts
- Conjunctivitis
- Cough
- Dizziness
- Dry eye
- Dyspnea
- Facial edema
- Flushing
- Ocular discharge
- Ocular pain
- Periorbital edema
- Proteinuria
- Tachycardia
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Moxetumomab pasudotox-tdfk
No pediatric safety and efficacy data.
- 1 Day – 18 Years
- No pediatric safety and efficacy data.
Moxetumomab Pasudotox-tdfk
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Moxetumomab Pasudotox-tdfk
Insufficient human data; pot for serious adv effects
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data; pot for serious adv effects |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication may cause serious (even fatal) blood vessel damage. It can cause fluid to leak from your small blood vessels into other parts of your body. Get medical help right away if you develop symptoms such as swelling of your face/arms/legs, sudden weight gain, shortness of breath, cough, or dizziness.<br /><br /> This medication may also cause serious (even fatal) blood cell and kidney damage. Get medical help right away if you develop symptoms of kidney damage (such as change in the amount of urine, dark urine), unusual bleeding/bruising, fever, vomiting, shortness of breath, fast heartbeat, unusual tiredness, confusion, or seizure. Careful monitoring by your doctor may decrease your risk. Your doctor may delay or stop treatment with this medication if you have severe side effects.
| Hairy cell leukemia | |
| C91.4 | Hairy cell leukemia |
| C91.40 | Hairy cell leukemia not having achieved remission |
| C91.42 | Hairy cell leukemia, in relapse |
| 0-9 | A-Z |
|---|---|
| C91.4 | Hairy cell leukemia |
| C91.40 | Hairy cell leukemia not having achieved remission |
| C91.42 | Hairy cell leukemia, in relapse |
Formulary Reference Tool